SCYNEXIS, Inc.
- SCYX
- NASDAQ
- Medical - Pharmaceuticals
- Antifungal Drug Development
- Triterpenoid Antifungals
$3.66
Today −0.27%Quote Oct 19, 2026, 08:00 PM UTC
−17.53%over the last month
Max drawdown −31.7%From 1-month high −31.7%3 months −5.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Employees
18
Market value
$36.4M
Quote Oct 19
Floor
$3.64
0.6% below price
Resistance
$4.46
21.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SCYXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free